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another study suggested the existence of O-glycosidically linked GlcNAc on extracellular proteins (11) , later structural analyses suggested that these workers were likely observing alpha-linked GlcNAc, a mucin like modification common in primitive eukaryotes (12) . Another early study showed that the GlcNAc-binding lectin wheat germ agglutinin (WGA) blocked ATP dependent RNA nuclear transport (13) . The characterization of β-O-GlcNAc in 1984 explained some of these preliminary observations and established OGlcNAc as a major form of intracellular protein glycosylation (14) . The nuclear pore proteins were among the first structurally characterized O-GlcNAc proteins (15, 16) . Since then, several laboratories have shown that hundreds, if not thousands, of proteins in the nucleus and cytoplasm are modified with O-GlcNAc (3, 4) .
Given the broad spectrum of proteins that contain this modification, there are likely to be many different functions for O-GlcNAc. Studies with the transcription factor Sp1 suggest that O-GlcNAc protects the protein from proteasome degradation (17) . Recent reports have shown that recognition of O-GlcNAc on peptides constitutes an important feature of MHC Class I antigen presentation (18) . Pulse-chase analyses have shown that the O-GlcNAc modification of some proteins is highly transient, with turnover rates similar to phosphorylation (19, 20) . Another study found that dynamic changes of O-GlcNAc modified proteins are associated with lymphocyte activation (21) . Several recent reports with phosphatase and kinase inhibitors have provided direct support for a relationship between O-phosphorylation and O-glycosylation of serine or threonine residues of some proteins (4, (22) (23) (24) . Consistent with the hypothesis that O-GlcNAc has a regulatory role, disruptions of the O-GlcNAc transferase homolog, SPY, in Arabidopsis results in impaired gibberellin signal transduction (25) . It is clear that O-GlcNAc is involved in very diverse aspects of cellular physiology ( Figure 2 ). The challenge for the coming years is to determine the precise contribution of OGlcNAc in the regulation of these systems.
Enzymes of O-GlcNAc Cycling
A Uridine Diphospho-N-Acetylglucosamine:polypeptide β-N-acetylglucosaminyltransferase (OGlcNAc Transferase; OGT; EC 2.4.1.94) was identified in extracts of rabbit reticulocyte membranes and rat liver using a synthetic peptide acceptor (26) . Latency studies confirmed that OGT is cytosolic and nuclear.
OGT was subsequently purified to near homogeneity from rat liver (27) , and its gene was cloned from rat by guest on September 14, 2017 http://www.jbc.org/ Downloaded from (28, 29) , C. elegans and human (30) . Recent studies using the Cre-Lox system in the mouse have shown that a functional OGT is essential for viability of embryonic stem cells and for mouse ontogeny (6) . Thus, OGlcNAc modification appears to be essential for eukaryotic cellular physiology. Consistent with the essential role of O-GlcNAc, there appear to be multiple mechanisms for the control of the O-GlcNAc transferase ( Figure 3 ). OGT has eleven tetratricopeptide repeats (TPR) at its N-terminus, which mediate the trimerization of the catalytic subunit (31) , as well as the interactions of the enzyme with many other proteins.
The TPR domain also appears to play a role in substrate selectivity (Comer and Hart, manuscript in preparation). OGT is a unique gene without other obvious family members, but is very highly conserved from C. elegans to human. In addition to the cloned 110 kDa catalytic subunit of OGT, there is a highly related 78 kDa subunit in several tissues (28) . This related isoform could be the product of proteolytic processing or alternative RNA transcript processing. The O-GlcNAc transferase itself is modified with OGlcNAc as well as tyrosine phosphate (28) , suggesting possible regulation through post-translational modifications. The activity of OGT is potently inhibited by UDP, the byproduct of the transfer reaction. The enzyme is sensitive to UDP-GlcNAc/UDP ratios over the entire physiologic range of sugar nucleotide concentration (micromolar to millimolar). In many cells the concentrations of UDP-GlcNAc approach that of ATP with as much as 2-5% of total glucose utilization channeled to making this sugar nucleotide (32) . Thus, local or global perturbations in the UDP-GlcNAc or UDP levels can modulate the activity of OGT. These features of the O-GlcNAc transferase and its environment suggest that it may be subject to complex regulatory mechanisms.
A cytosolic and nuclear β-N-acetylglucosamindase (O-GlcNAcase) with a neutral pH optimum and selectivity toward O-linked GlcNAc has also been identified and purified (33) . Several useful inhibitors, such as PUGNAC (34) have been identified. Treatment of several different cell types with this inhibitor results in an overall increase in O-GlcNAc levels on numerous proteins (35) . Current data suggest that in many systems the regulation of O-GlcNAc cycling will have important consequences for the regulation of protein function. For example, a recent study showed that, when expressed in the cytoplasm and nucleus, a Golgi enzyme that caps O-GlcNAc and prevents its normal cycling is lethal to cells (36) (CTD) appear to be reciprocal (7) . The glycosylation of the CTD sequence induces a turnlike structure, which could dramatically alter the conformation of the domain (42) . Such conformational changes in the CTD could affect the specificity of interactions with other components of the transcription machinery.
Phosphorylation of the CTD is associated with transcript elongation and RNA processing (43, 44) . Therefore, it is plausible that O-GlcNAc on the CTD may be involved in events prior to the elongation phase of the transcription cycle. There is evidence that O-GlcNAc plays a role in controlling both the turnover and transactivation activities of key transcription factors, such as SP1 and estrogen receptors (41) . Some researchers have proposed that O-GlcNAc modulates or mediates the assembly of transcriptional complexes, leading to the activation of specific genes (7, 22) . While it is clear that O-GlcNAc is enriched on proteins involved in eukaryotic gene transcription, further work is necessary to elucidate its specific roles in this complex process.
Gupta, Datta and colleagues have shown that O-GlcNAc plays a direct role in regulating protein translation (45) . The eukaryotic initiation factor 2 (eIF-2) is a translation initiation factor that is inactivated when phosphorylated by any of several eIF-2 kinases. The O-GlcNAc modified form of the eIF-2 associated by guest on September 14, 2017 http://www.jbc.org/ Downloaded from protein, p67, binds to eIF-2 and prevents the action of the inhibitory eIF-2 kinases. Under conditions of serum starvation or heme depletion, a normally latent deglycosylase removes the O-GlcNAc from p67, which causes p67 to dissociate from eIF-2 and also accelerates the proteolytic degradation of p67. As a result of p67 dissociation, eIF-2 becomes subject to the action of eIF-2 kinases, hence shutting down protein translation. It will require the work of many laboratories to sort out the functions of O-GlcNAc in the regulation of protein synthesis, but it is clear that it plays a critical role in this process. 
Dynamic -O-GlcNAc Modification of Cytoskeletal Proteins

Potential Implications of -O-GlcNAc for Human Disease O-GlcNAc and Neurodegenerative Diseases
O-GlcNAc is abundant in the brain, particularly on cytoskeletal proteins such as neurofilaments, microtubule associated proteins, clathrin assembly protein and the β-amyloid precursor protein (46, (49) (50) (51) .
Disruptions of O-GlcNAc modification of some of these proteins may contribute to certain neurodegenerative disorders. For example, the OGT gene itself maps on the X-chromosome to the same locus as X-linked Parkinson Dystonia (6). The microtubule-associated protein, Tau, which is a major component of neurofibrillary tangles in Alzheimer's diseased brains, is multiply O-GlcNAc modified in normal brains (49) .
In contrast, Tau is hyperphosphorylated in association with Alzheimer's disease (52) . The β-amyloid by guest on September 14, 2017 http://www.jbc.org/ Downloaded from precursor protein (APP), which gives rise to the Alzheimer's disease associated neurotoxic β-amyloid peptide upon proteolysis, is also O-GlcNAc modified (51) . We have hypothesized that some neurodegenerative diseases might result directly from decreased glucose metabolism by aging neurons, which results in a gradual reduction in O-GlcNAc modification of key cytosolic and nuclear proteins. This gradual failure to add O-GlcNAc could subsequently lead to the abnormal phosphorylation of many proteins, but the abundant cytoskeletal proteins would manifest the effect first.
O-GlcNAc and Cancer
As noted above, O-GlcNAc is present on many transcription regulatory proteins. Mutations of many of these proteins contribute to the oncogenic phenotype. Some of these mutations may exert their effects in part by disruption of O-GlcNAc mediated regulation of these proteins. For example, the c-myc oncogene is glycosylated in its transactivation domain at Thr-58, which is also the mutational hotspot found in a large percentage of Burkitt's lymphomas from human patients. Interestingly, this glycosylation site is also an important phosphorylation site that regulates c-myc transcriptional activity (53) . Clearly the many site proteins, the reader should refer to previous reviews (3, 4) . Nevertheless, the current list of O-GlcNAc modified proteins is decidedly incomplete, as detection of O-GlcNAc proteins present in soluble cell extracts reveals thousands of proteins that contain this modification. 
